MYLAN-CILAZAPRIL TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

CILAZAPRIL (CILAZAPRIL MONOHYDRATE)

Beschikbaar vanaf:

MYLAN PHARMACEUTICALS ULC

ATC-code:

C09AA08

INN (Algemene Internationale Benaming):

CILAZAPRIL

Dosering:

2.5MG

farmaceutische vorm:

TABLET

Samenstelling:

CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 2.5MG

Toedieningsweg:

ORAL

Eenheden in pakket:

100

Prescription-type:

Prescription

Therapeutisch gebied:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0122806004; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2009-07-10

Productkenmerken

_ _
_ _
_Page 1_
PRODUCT MONOGRAPH
PR MYLAN-CILAZAPRIL
Cilazapril
Monohydrate Tablets
1 mg, 2.5 mg, 5 mg
Angiotensin Converting Enzyme Inhibitor
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Submission
Control No.: 257402
Date of Revision:
November 16, 2021
_ _
_ _
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
5
ADVERSE
REACTIONS............................................................................................12
DRUG INTERACTIONS
............................................................................................19
DOSAGE AND ADMINISTRATION
.........................................................................23
OVERDOSAGE
.........................................................................................................26
ACTION AND CLINICAL
PHARMACOLOGY.........................................................27
STORAGE AND STABILITY
....................................................................................30
SPECIAL HANDLING INSTRUCTIONS
...................................................................30
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................30
PART II: SCIENTIFIC INFORMATION
..........................................................................
32
PHARMACEUTICAL INFORMATION
.....................................................................32
CLINICAL TRIALS
...................................................................................................33
DETAILED
PHARMACOLOGY..........................................